Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
FMT trials MIMic (NCT03772899) is a phase 1 trial 23 enrolling patients with unresectable or metastatic cutaneous melanoma measurable disease as per RECIST v.1.1 criteria with no previous anti-PD-1 treatment who underwent FMT and were treated with anti-PD-1 (either pembrolizumab or nivolumab)
They can be given directly to patients if needed
Understanding these forms and their benefits can help you choose the right product for your specific needs
Regularly check the expiration date, and when disposing of unused or expired capsules, do not flush or pour them down the drain
The recommended starting dose is 3.75/23 mg for two weeks, and your provider will increase from there
US$ 22.30
US$ 29.80
US$ 25.29
:format(webp)/drugs/tR_jeVKwM0GRlnvMNpoCU/original/kdt7hbivdg8isf7q5dpibs79k4mvh03f.png)
US$ 27.84
